Company Media Investors & Corporate 2020 Immuron's stock pulls back but still nearly doubles after stock offering

Immuron's stock pulls back but still nearly doubles after stock offering

Shares of Immuron Ltd. IMRN, -2.72% nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a registered direct offering of 1.07 million American depositary.... https://www.marketwatch.com/story/immurons-stock-pulls-back-but-still-nearly-doubles-after-stock-offering-2020-07-21

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.

The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.

Payment Options

Contact Information

Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
Phone: +613 8892 4854
Fax: +613 9899 8533

Filter Categories

Immuron's stock pulls back but still nearly doubles after stock offering

Partners

Secure Shopping

Get Connected

About Us

Information

Payment Options

Contact Information